AML scientists have extensive experience in the development of CLIA-validated IHC assays, pharmDx IHC assays, and IHC-based companion diagnostics. AML has on-site pathologists to assist with the optimization and standardization of new IHC targets.
- AML possesses a comprehensive collection of IHC assays.
- AML consistently incorporates new IHC assays with a rapid validation time.
- AML works with clients to develop custom IHC assays, and AML offers solutions to optimize existing IHC assays.
- Our group has a strong history of LDT and companion diagnostic development (most recently the standardization and harmonization of IHC PD-L1 companion diagnostics).
American Molecular Laboratories has observed that the most reliable and consistent IHC studies are performed with single or dual antibody staining.
Examples of previous oncology-related IHC assays are shown in Table 1.
Table 1. Immunohistochemistry Tests (truncated list)
|Cleaved Caspase 3 (CC3)||HER2|
|Cleaved PARP (cPARP)||PD-L1|
Figure Legend. AML’s Comprehensive tumor profiling combines Next-Generation Sequencing (NGS) and Immunohistochemistry to analyze the underlying biology of cancer.